New combo therapy aims to shrink tumors, save organs in rare head cancer

This study is testing if adding a new immunotherapy drug called cemiplimab to standard chemotherapy before surgery works better than chemotherapy alone for advanced sinonasal squamous cell carcinoma, a rare cancer in the nasal cavity and sinuses. The goal is to see if the combination shrinks tumors more effectively, helps patients live longer without the cancer returning, and potentially allows surgeons to preserve critical structures like the eye socket. About 108 adults with this specific cancer who have not yet had treatment will be randomly assigned to receive either the standard chemo or the chemo plus immunotherapy before their planned surgery and radiation.